Trial
NCT02993991
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University Health Network, Toronto
Collaborators
Mirati Therapeutics Inc.; AstraZeneca
Condition
Squamous Cell Carcinoma, Head And Neck
Intervention
Mocetinostat
Why stopped
The study has been terminated due to a change in internal prioritization and not due to any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-29